Metabolite Card
Formula: C6H14O12P2 (339.9961)
SMILES: O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H](OP(O)(O)=O)[C@@H]1O
Synonyms [en]
alpha-D-Glucose 1,6-bisphosphate; alpha-D-Glucose 1,6-biphosphate; Glucose 1,6-bisphosphate; D-Glucose 1,6-bisphosphate; UNII-DRX17R6AM2; a-D-Glucose 1,6-bis(dihydrogen phosphate)
Last reviewed on 2024-06-28.
Cite this Page
alpha-D-Glucose 1,6-bisphosphate. 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000006244). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
Glucose 1,6-diphosphate (G-1,6-P2) is considered to be a major regulator of carbohydrate metabolism. It has been demonstrated that G-1,6-P2 is a potent activator (deinhibitor) of skeletal muscle phosphofructokinase (PFK) and phosphoglucomutase, while being an inhibitor of hexokinase (see Ref. 2). In addition, G-1,6-P2 has been shown to inhibit 6-phosphogluconate dehydrogenase in various rat tissues and fructose 1,6-bisphosphatase in bovine liver. Various factors and conditions affect the tissue content of G-1,6-P2. Specifically, anoxia induces a rapid fall in the content of G-l,6-P2 in the brain. Glucose 1,6-diphosphate has been recognized as a regulatory signal implicated in the control of metabolism, oxygen affinity of red cells, and other cellular functions. The levels of G 1,6-P2 are reduced in the liver and in the muscle of rats with experimentally induced diabetes. In muscle of genetically dystrophic mice, a decrease in the levels of G 1,6-P2 has been found, probably resulting from enhancement of glucose 1,6-P2 phosphatase activity. G 1,6-P2 is an inhibitor of hexokinase and its level is increased significantly after 5 min of exercise (~25%) and then decreased continuously. G 1,6-P2 is a potent allosteric activator of phosphofructokinase, and is markedly decreased in muscles of patients with glycogenosis type VII (muscle phosphofructokinase deficiency) and type V (muscle phosphorylase deficiency). Chronic alcohol intake produces an increase in the concentration of G 1,6-P2 in human muscle before the first sign of myopathy appears. When myopathy is present the level decreases to be similar to healthy humans. These changes could contribute to the decline in skeletal muscle performance (PMID:1449560, 2018547, 2003594, 3407759).
DBLinks
- CAS Registry Number: 10139-18-1
- PubChem CID: 82400
- ChEBI: 18148
- HMDB: HMDB0003514
- LipidMaps:
- KEGG: C01231
- BioCyc:
- NCBI MeSH: glucose-1,6-bisphosphate
- Wikipedia: Glucose_1,6-bisphosphate
Other DBLinks
- CAS Registry Number: 10139-18-1
- PubChem: 82400
- ChEBI: ChEBI:18148
- HMDB: HMDB0003514
- KEGG: C01231
- NCBI MeSH: glucose-1,6-bisphosphate
- Wikipedia: Glucose_1,6-bisphosphate
- DrugBank: DB02835
- RefMet: RM0136232
- MoNA: EMBL_MCF_2_0_HRMS_Library000506
- MoNA: PR100628
- MoNA: PS037703
- MoNA: PS037707
- MoNA: PS037708
- MoNA: PS037709
- Metlin: METLIN_154
- Coconut NaturalProduct: CNP0362991.1
Class / Ontology
- WishartLab ClassyFire: [Carbohydrates and carbohydrate conjugates] Carbohydrates and carbohydrate conjugates
- RefMet: [Hexose phosphates] Hexose phosphates
| ID | EC Number | Name |
|---|---|---|
| KEGG:R00949 | 2.7.1.10 | ATP:D-glucose-1-phosphate 6-phosphotransferase |
| KEGG:R00960 | 2.7.1.41 | D-glucose-1-phosphate:D-glucose-1-phosphate 6-phosphotransferase |
| KEGG:R01660 | 2.7.1.106 | 3-phospho-D-glyceroyl-phosphate:alpha-D-glucose-1-phosphate 6-phosphotransferase |
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| WikiPathways:WP3604 | Biochemical pathways: part I |
| PathBank:SMP0120838 | Glycogenosis, Type VI. Hers Disease |
| PathBank:SMP0120617 | Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis |
| PathBank:SMP0120621 | Sucrase-Isomaltase Deficiency |
| PathBank:SMP0000552 | Glycogen Synthetase Deficiency |
| PathBank:SMP0000556 | Mucopolysaccharidosis VII. Sly Syndrome |
| PathBank:SMP0063673 | Starch and Sucrose Metabolism |
| PathBank:SMP0120837 | Glycogenosis, Type IV. Amylopectinosis, Anderson Disease |
| PathBank:SMP0120616 | Glycogen Synthetase Deficiency |
| PathBank:SMP0120620 | Mucopolysaccharidosis VII. Sly Syndrome |
| PathBank:SMP0000555 | Glycogenosis, Type VI. Hers Disease |
| PathBank:SMP0087345 | Starch and Sucrose Metabolism |
| PathBank:SMP0120836 | Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis |
| PathBank:SMP0120840 | Sucrase-Isomaltase Deficiency |
| PathBank:SMP0120618 | Glycogenosis, Type IV. Amylopectinosis, Anderson Disease |
| PathBank:SMP0000553 | Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis |
| PathBank:SMP0000557 | Sucrase-Isomaltase Deficiency |
| PathBank:SMP0087252 | Starch and Sucrose Metabolism |
| PathBank:SMP0120835 | Glycogen Synthetase Deficiency |
| PathBank:SMP0120839 | Mucopolysaccharidosis VII. Sly Syndrome |